Membranolytic peptide research that explains a designed, pH‑responsive approach to trigger immunogenic cell death and enhance cancer immunotherapy.
Key Takeaways
- Rational design for facilitating innovative cell death modes can substantially aid advances in antitumour therapy 1 , 2
- This mode of mLCD was induced by the synthetic-acid-responsive membranolytic peptide (aMP)
- AMP C16 -CA 50 activated an inflammatory transcriptional program in tumour cells